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Background: Advanced urothelial carcinomas represent a considerable clinical challenge as they are difficult to treat.
Platinum-based combination regimens obtain response rates ranging from 40 to 70% in first-line therapy of advanced
urothelial carcinoma. In the majority of cases, however, the duration of these responses is limited, and when progression
occurs, the outcome is generally poor. Therefore, novel therapeutic strategies are urgently needed. The purpose of the
current research is to investigate the anticancer effects and the mode of action of the marine triterpene glycoside
frondoside A in p53-wild type and p53-deficient human urothelial carcinoma cells.
Methods: Activity of frondoside A was examined in the human urothelial carcinoma cell lines RT112, RT4, HT-1197, TCC-
SUP, T-24, and 486p. Effects of frondoside A on cell viability, either alone or in combination with standard cytotoxic agents
were investigated, and synergistic effects were analyzed. Pro-apoptotic activity was assessed by Western blotting and
FACS, alone and in combination with a caspases-inhibitor. The impact of functional p53 was investigated by siRNA gene
silencing and the p53 inhibitor pifithrin-α. Effects on autophagy were studied using LC3B-I/II and SQSTM/p62 as markers.
The unpaired Student’s t-test was used for comparison of the data sets.
Results: Frondoside A shows high cytotoxicity in urothelial carcinoma cells with IC50s ranging from 0.55 to 2.33 μM while
higher concentrations of cisplatin are required for comparable effects (IC50 = 2.03 ~ 5.88 μM). Induction of apoptosis by
frondoside A was associated with the regulation of several pro-apoptotic factors, like caspase-3, -8, and -9, PARP, Bax,
p21, DNA fragmentation, and externalization of phosphatidylserine. Remarkably, inhibition of p53 by gene silencing or
pifithrin-α pretreatment, as well as caspase inhibition, did not suppress apoptotic activity of frondoside A, while cisplatin
activity, in contrast, was significantly decreased. Frondoside A inhibited pro-survival autophagy, a known mechanism of
drug resistance in urothelial carcinoma and showed synergistic activity with cisplatin and gemcitabine.
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Conclusions: A unique combination of properties makes marine compound frondoside A a promising candidate for the
treatment of human urothelial carcinomas.
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Advanced urothelial carcinomas (UCs) represent a consid-
erable clinical challenge as they are difficult to treat.
Platinum-based combination regimens obtain response
rates ranging from 40 to 70% in first-line therapy of ad-
vanced urothelial carcinoma (UC). In the majority of
cases, however, the duration of these responses is limited,
and when progression occurs, the outcome is generally
poor [1]. So far, the results of single agents or combina-
tions administered in the salvage setting have been rather
disappointing [2]. In Europe, vinflunine is the only
approved second-line therapy to date, and until recently,
no treatment regimen was officially recommended in the
USA for salvage therapy [3]. However, on May 18th 2016,
the PD-L1 inhibitor atezolizumab was approved by the
U.S. Food and Drug Administration (FDA) for the treat-
ment of patients with locally advanced or metastatic UC
who experienced disease progression during or following
platinum-containing chemotherapy. In fact, atezolizumab
achieved objective response rates of 26% (95% CI 18–36)
in the IC2/3 group, 18% (13–24) in the IC1/2/3 group,
and 15% (11–19) in all treated patients of a phase II clin-
ical trial (IMvigor210) with some long-term responses
lasting for more than 12 months [4, 5]. Nevertheless,
patients, especially without PD-L1 expression, may not
significantly benefit from this immune check-point inhib-
ition, emphasizing an unmet need for novel therapeutic
strategies [4].
p53 deficiency has been detected in more than 60% of
UC [6], and has been associated with aggressive biology
[7, 8]. In addition, it has been speculated that it could
serve as a prognostic marker for the response of UC to
systemic treatment [7, 8]. Furthermore, p53 deficiency
or inactivation is a known mechanism of drug resistance
in human malignancies [9].
Another factor playing a role in chemotherapy resist-
ance is autophagy [10, 11]. Macroautophagy (referred as
autophagy) is a basic cellular catabolic process which
leads to selective or non-selective degradation of pro-
teins and organelles by the lysosome system [12]. It in-
cludes the formation of double-membrane vesicles called
autophagosomes, which fuse with lysosomes, resulting in
the degradation and recycling of sequestered contents
[12]. Most of anticancer drug treatment-induced autoph-
agy was identified to have pro-survival properties and
therefore, this process is believed to be one of the key
mechanisms of drug resistance [10, 11]. Autophagyallows cancer cells to use their entire resources to
survive diverse apoptosis inducing signals, including
chemotherapy-induced apoptosis [11]. Recently, autoph-
agy has been reported to be an important drug resist-
ance and pro-survival mechanism in UC [10, 13].
Therefore, pharmacological inhibitors of autophagy may
prevent development of resistance and enhance cyto-
toxic activity of known anticancer drugs [10, 11].
Frondoside A (FrA) is a natural bioactive compound,
initially isolated from the sea cucumber Cucumaria fron-
dosa [14]. Recent studies revealed promising anticancer
activity of FrA in vitro and in vivo, which is exerted
through its pro-apoptotic, antimetastatic, and immunosti-
mulatory activity (for review see [15, 16]). Remark-
ably, we were able to demonstrate that FrA inhibits
pro-survival autophagy in prostate cancer cell lines
resistant to standard therapies and induces apoptosis
[17]. However, to date, no data are available on the
activity of FrA in human UC.
In this study we examined the effect of the triterpene
glycoside FrA in human UC cells bearing either wild-type
or mutant p53. We explored the relevance of p53 for the
anti-cancer effect of the marine natural compound, as well
as the effect of FrA on autophagy in UC cells.
Methods
Reagents and antibodies
The marine triterpene glycoside frondoside A (FrA) was
isolated from the sea cucumber Cucumaria okhotensis as
previously described [18]. The purity of the individual
compound was verified by HPLC, 1H and 13C NMR
spectroscopy. Other reagents and antibodies are listed in
Additional file 1.
Cell lines and culture conditions
The human urothelial cancer cell lines RT4 (p53 wild
type), HT-1197 (p53 wild type), TCC-SUP (mutant p53),
T-24 (mutant p53), were purchased from ATCC (Manas-
sas, VA, USA) [19]. RT112 (p53 wild type) cell line was
purchased from DSMZ (Braunschweig, Germany) [19].
486p cell line (unknown p53 mutational status) was pre-
viously generated and characterized by Elliott et al. from
grade IV TCC of the bladder metastatic to a supraclavi-
cular node of 61-year-old white male patient [20, 21];
ethics and consent statements can be found in the corre-
sponding references [20, 21]. 486p cells were kindly pro-
vided by the Urology department of University Medical
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conditions are described in the Additional file 1.
In vitro cell viability assays
Cytotoxicity profiles of single compounds and drug
combinations were evaluated by MTT or trypan blue-
based viability assays as described previously [22]. The
duration of treatment was 48 h, unless otherwise stated.
Examination of synergistic/antagonistic effects of drug
combinations
Determination of synergistic, antagonistic, or additive
effects of compounds used in combination assays was
performed using the Chou-Talalay method as previously
described [23]. The combinational index (CI) was calcu-
lated with the CompuSyn v.1.0. Software (ComboSyn,
Inc., Paramus, NJ, USA). Fa (fraction affected) is defined
as the non-survival fraction at a certain dose of com-
pounds or their combinations. Synergism is defined as a
CI < 0.85, whereas antagonism has a CI > 1.2. A CI of
0.85 to 1.2 is considered an additive effect.
Detection of apoptotic cells by annexin-V-FITC/PI double
staining
Induction of apoptosis was examined by FACS analysis
with an annexin-V-FITC and propidium iodide (PI)
double staining. The experiment was performed as pre-
viously described with slight modifications [24]. In brief,
cells were pre-incubated overnight in 6-well plates
(0.2 × 106 cells/well), pretreated for 1 h with the medium
(1 mL/well) with or without addition of the caspase in-
hibitor zVAD (100 μM). The compound of interest was
then added and the cells were incubated for additional
48 h. After treatment, cells were harvested with a trypsin
solution, stained, and analyzed using a FACS Calibur
(BD Bioscience) and BD Bioscience Cell Quest Pro soft-
ware (BD Bioscience).
Cell cycle and DNA fragmentation analysis
The cell cycle distribution was analyzed by flow cytome-
try using PI staining as described before [22]. In brief,
cells were pre-incubated overnight in 6-well plates
(0.2 × 106 cells/well) and treated with FrA. After 48 h of
treatment, cells were trypsinized, fixed with 70% EtOH/
H2O (v/v), stained, and analyzed. The results were gen-
erated and quantitatively analyzed using a FACS Calibur
as above and BD Bioscience Cell Quest Pro software.
Western blotting
Preparation of protein extracts and Western blotting was
performed as described previously [23]. In brief 1 × 106
cells/well were seeded in Petri dishes (ø 10 cm TC Dish
(Sarstedt, Numbrecht, Germany) 10 mL/dish), incubated
overnight and treated with drugs for 48 h in 10 mL/dish.Cells were harvested using a cell scraper, washed, and
lysed. Lysates were frozen overnight at −20 °C and then
centrifuged. Protein concentration in the supernatants
was determined by Bradford assay. Total protein extracts
(20–30 μg/sample) were subjected to electrophoresis in
SDS-polyacrylamide gels at 120 V, and transferred from
gel to a 0.2 μm pore PVDF membrane. The membrane
was blocked and incubated with the primary and second-
ary antibodies according to the manufacturers’ protocol
(for antibodies used, see Additional file 1: Table S1).
Signals were detected using the ECL chemiluminescence
system (Thermo Scientific, Rockford, IL, USA) according
to the manufacturer’s protocol.Silencing of p53 by siRNA transfection
Silencing of p53 gene was performed using siRNA transfec-
tion technique and Lipofectamine® RNAiMAX Transfec-
tion Reagent (Invitrogen, UK). RT112 cells were pre-
incubated overnight in 6-well plates (1 × 105 cells/well in
2 mL) in antibiotics-free RPMI media. The solutions (a)
and (b) were prepared: (a) 20 μL of 100 pmol/μL siRNA
(total amount 2 nmol) + 230 μL of Opti-MEM media; (b)
7.5 μL of Lipofectamine® RNAiMAX Transfection Re-
agent + 242.5 μL of Opti-MEM media. The solutions
were incubated for 5 min, mixed and further incubated
for 20 min. The media in the wells were replaced with
2 mL of fresh antibiotics-free RPMI media and 0.5 mL of
(a) + (b) mixture were added to each well by dropping.
After 72 h of incubation the media was aspirated, cells
were washed PBS, and fresh antibiotics-free RPMI media
(drug-containing or drug-free) was added (2 mL/well).
Then the cells were either immediately harvested for
Western blotting analysis or incubated for 48 h and ana-
lyzed by FACS.
Duplexed siRNA were purchased from Eurofins Geno-
mics (Ebersberg, Germany). The gene target sequences
(5′→ 3′) are: p53 siRNA (NM_000546_Val): GACUC
CAGU GGUAAUCUAC(dTdT); scrambled siRNA (Non
Specific Control 47% GC): AGGUAGUGUAAUCGCC
UUG(dTdT).Immunofluorescence analyses
The experiments were performed as described before
[17]. In brief, RT112 cells (5 × 104 cells/chamber) were
treated for 48 h with investigated drugs, fixed and
permeabilized. Next, cells were stained with anti-LC3B-
I/II antibody overnight at 4 °C followed by incubation
with secondary anti-rabbit Alexa Fluor 488-conjugated
antibody. Samples were washed and covered with DAPI-
based ProLong® Gold reagent (Life Technologies) and
directly analyzed with AxioScope.A1 (Carl Zeiss) micro-
scope with the AxioVision40 V4.8 software (Carl Zeiss
Imaging Solutions).
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Statistical analyses were performed using GraphPad
Prism software v. 5.01 (GraphPad Prism software Inc.,
La Jolla, CA, USA). Data are presented as mean ± SEM
(standard error of mean). All experiments were per-
formed in triplicates, and repeated at least three times.
The unpaired Student’s t-test was used for compari-
son of two groups. Statistical significance was labeled
as: *p < 0.05, **p < 0.01, ***p < 0.001.Results
FrA reduces urothelial carcinoma cell viability
Frondoside A (FrA, Fig. 1a) exerted cytotoxic activity in
all human UC cell lines tested, with IC50s ranging from
0.55 to 2.33 μM. Remarkably, cisplatin (Cis) used as a
reference drug was less effective in the same assays,
having 2–6 fold higher IC50s (Fig. 1b). The urinary blad-
der transitional cell carcinoma cell line RT112 cells
showed highest sensitivity to FrA, and was chosen as a
model to further explore the molecular mechanisms of
anticancer action of this marine natural compound.FrA induces apoptosis in urothelial carcinoma cells
Next, we examined the effect of FrA on the induction of
apoptosis in human UC cells. Hallmarks of apoptosis, in-
cluding dose-dependent caspase- and PARP-cleavage
(Fig. 2a), DNA fragmentation (Fig. 2b), as well as phos-
phatidylserine externalization (Fig. 2c), were observed in
FrA-treated RT112 cells. In addition, the effect of FrA
on several pro- and anti-apoptotic proteins was exam-
ined by Western blotting. The upregulation of pro-
apoptotic Bax and p21 was observed in FrA-treated
RT112 cells (Fig. 2a), while no alterations of p-Akt, p53,
Bad, Pak1, survivin, and Bcl-2 were found (data not
shown). FACS analysis did not reveal any significant
effect of FrA on cell cycle phase distribution of human
UC cells (data not shown).Fig. 1 Structure and effect of FrA on the viability of human urothelial canc
determined with a trypan blue-based viability assay. Cells were treated withFrA-induced apoptosis is caspase- and p53-independent
Various cytotoxic anti-cancer therapies act through
pro-apoptotic caspases- and/or p53-related pathways.
However, these processes are often defected in human
cancer cells, which may result in chemotherapy resist-
ance [9, 25]. Therefore, we investigated the role of these
two pathways in FrA-induced apoptosis. We could show
that FrA induces dose-dependent caspase-3, -8, and -9
cleavage in RT112 cells (Fig. 2a). However, the inhibition
of caspases activity by pretreatment with the pan-
caspase inhibitor zVAD did not decrease the apoptotic
cells rate (Fig. 2c, d). At the same time, the pro-
apoptotic effect of anisomycin–a well characterized
inducer of classical apoptosis–was significantly inhibited
by the zVAD (Fig. 2d). Based on these results, we con-
clude that FrA is able to induce apoptosis in UC cells in-
dependently of caspase activity. The observed caspase
cleavage is probably an unspecific effect, which can
occur secondary to other FrA-induced cytotoxic events.
RT112 cells are known to harbor wild-type p53 gene
[19]. FrA did not alter the total level of p53 of RT112
cells (Fig. 3a). Silencing of the p53 gene expression using
specific siRNA resulted in a substantial reduction of p53
protein level in RT112 cells (Fig. 3b). Remarkably, the
cytotoxic effect of cisplatin was significantly decreased
in the cells with reduced p53 level, while no inhibition
of FrA efficacy was observed (Fig. 3c). In line with this
finding, pretreatment with pifithrin-α–a chemical inhibi-
tor of p53 activity–suppressed cytotoxicity of cisplatin
(Fig. 3d), but not the activity of FrA (Fig. 3e) suggesting
that FrA remains active in human cancer cells bearing
mutated non-functional p53.
FrA affects MAPK in RT112 cells
Mitogen activated protein kinases (MAPK) can be
involved in both proliferative or pro-apoptotic mecha-
nisms in human UC [26, 27]. Therefore, we evaluated
the effect of FrA on MAPK in RT112 cells. After short-
term treatment (1 h), FrA lead to suppression of p38er cells. a Structure of frondoside A (FrA). b Cytotoxicity of FrA,
FrA or Cis for 48 h
Fig. 2 Induction of caspase-independent apoptosis in FrA-treated cells. a Western blotting analysis of protein extracts of RT112 cells treated with
FrA for 48 h. b Cell cycle analysis of RT112 cells treated with FrA for 48 h. Apoptotic cells are detectable as a sub-G1 population. Cell cycle phase
distribution was quantified using the Cell Quest Pro software. c, d Flow cytometry analysis of RT112 cells treated with FrA using an annexin-V-FITC/PI
double staining (c) and quantification of positive cells (d). Cells were pretreated with 100 μM of the pan-caspase inhibitor zVAD for 1 h and then
treated with indicated concentrations of FrA or with anisomycin (Aniso, positive control) for 48 h. Apoptotic cells appearing in the right lower and
upper quadrants were quantified using the Cell Quest Pro software
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tions ≥ 5 μM), but activated JNK1/2 (Fig. 4a). Activation
of JNK1/2 was also observed after long-term treatment
with FrA (48 h, Fig. 4b). To further explore the role of
JNK1/2 activation in response to FrA treatment, we
investigated the effect of the well-established JNK1/2
inhibitor SP600125 on FrA-mediated cytotoxicity. Com-
bining FrA and SP600125 clearly showed synergistic
cytotoxic effects in MTT-based Chou-Talalay assays
(Fig. 4c), indicating a prosurvival role of JNK1/2 activa-
tion in UC cells following FrA treatment.
Autophagy
Induction of pro-survival autophagy by different anti-
cancer agents is a recently characterized phenomenon in
different human cancers, including UC [10, 11, 28]. Ofnote, pro-surival autophagy was identified as one of the
main mechanisms of drug-resistance in UC [10, 11, 13, 28].
LC3 (isoforms LC3B-I and LC3B-II) and p62 (also known
as SQSTM1) proteins are major effectors of this process
and therefore are often used as autophagy alteration
markers [29]. During autophagy, LC3-I converts to LC3-II,
which is required for the autophagosome membrane for-
mation. p62 is an autophagosome cargo protein which
binds other proteins for selective autophagy [29]. Accumu-
lation of LC3-I/II and p62 as well as accumulation of LC3-
positive organelles (autophagosomes) indicate inhibition of
autophagy [29]. We could demonstrate that FrA induces
time- and dose-dependent accumulation of these
autophagy-related proteins (Fig. 5a, b). Interestingly, in
RT112 cells, the maximal p62 protein level was observed
after 2 h of treatment, whereas maximal LC3B-II levels
Fig. 3 Effect of p53 silencing on cytotoxicity of FrA. a, b Western blotting analysis of p53 expression in RT112 cells treated with FrA for 48 h (a) or
transfected with p53 siRNA versus cells transfected with scrambled siRNA (b). c Viability of transfected cells treated with FrA or Cis for 48 h. Cell
viability was analyzed by flow cytometry analysis using annexin-V-FITC/PI double staining. Viable cells appearing in the lower left quadrant were
quantified using the Cell Quest Pro software. d, e Effect of pifithrin-α (Pif-α)–an inhibitor of p53 activity–on the cytotoxic activity of FrA and Cis in
nontransfected RT112 cells. Cells were pretreated with 40 μM of Pif-α for 30 min and then cotreated with FrA (d) or Cis (e) for 48 h. Cell viability
was determined using MTT-assay
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of autophagy in UC cells. Additionally, increased LC3B-I/
II-immunostaining of RT112 cells treated with FrA (Fig. 5c)
was found being a result of a treatment-induced accumula-
tion of autophagosomes (Fig. 5d).
Finally, similar profiles were observed for cells treated
with the well-established autophagy inhibitors BafA1
and CQ when compared to FrA (Fig. 5a–c), indicatingFig. 4 Effect of FrA on mitogen-activated protein kinases (MAPK).
a, b RT112 cells were treated with FrA for 1 h (a) or 48 h (b), and then
protein extracts were analyzed by Western blotting. c Effect of SP600125
(a specific JNK1/2 inhibitor) on the survival of RT112 cells treated with
FrA. Drugs were combined in the constant molar ratio C(FrA) :
C(SP600125) = 1 : 15, and cells were cotreated with the individual drugs
or their combination for 48 h. The data were generated using trypan
blue-based viability assay. Cells were pretreated with SP600125 in
50 μL/well culture media for 1 h. The combinational index (CI)
was calculated with the CompuSyn v.1.0. softwarecomparable molecular effects of these three compounds,
i.e. inhibition of autophagy.
FrA enhances cytotoxic effects of cisplatin and
gemcitabine
The effect of FrA was evaluated in combination with
two standard chemotherapeutic agents frequently ap-
plied in advanced UC, namely cisplatin and gemcitabine.
Remarkably, FrA was strongly synergistic in combination
with both drugs in RT112 cells (Fig. 6a, b).
Discussion
Cisplatin based combination therapy is the standard of
care for first line therapy of advanced or metastasized
UC. However, despite initial response rates of 40–70%,
relapses occur in the majority of patients due to the
development of resistance [1, 10, 30]. Among others,
overexpression of ERCC1, Nrf2, CTR1/2, hENT1 and
BRCA1, expression of specific miRNA, epithelial-
mesenchymal transition, loss of p53 function, and
pro-survival autophagy were identified as potential
mechanisms of resistance [10, 30].
In this study, we investigated the anticancer activity of
the marine natural compound FrA in human UC cells.
FrA decreased the viability of UC cells more effectively
than cisplatin at equimolar concentrations. The marine
compound exerted its cytotoxic action through the
induction of apoptosis. This process was associated with
the alteration of several pro-apoptotic factors, like
cleaved caspases-3, -8, and -9, cleaved PARP, Bax and
p21, leading to dose-dependent DNA fragmentation and
phosphatidylserine externalization. In addition, FrA acti-
vated JNK1/2, while p38 and ERK1/2 were inhibited.
JNK1/2 may have either pro- or anti-apoptotic functions,
depending on cell type, nature of the death stimulus and
Fig. 5 Inhibition of autophagy in urothelial cancer cells under FrA-treatment. a, b Time- (a) and dose-dependent (b) effects of FrA, bafilomycin A1 (BafA1),
and chloroquine (CQ) on levels of LC3B-I/II and SQSTM/p62 in RT112 cells. Cells were treated for 0.5–48 h (a) or for 48 h (b), followed by protein extraction
and analysis by Western blotting. The established autophagy inhibitors BafA1 and CQ were used as positive controls. c, d Accumulation
of autophagosomes/autolysosomes. Cells were treated with the indicated concentrations of FrA, BafA1, and CQ for 48 h, fixed, permeabilized, and
incubated with the anti-LC3B-I/II antibody, followed by treatment with Alexa Fluor 488-conjugated secondary antibody. The pictures were
made at × 400 (c) or × 1000 (d) magnification. LC3B-I/II-positive organelles (autophagosomes/autolysosomes) appearing as dots are indicated by arrows
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more pronounced cytotoxic effect of FrA, JNK1/2 activa-
tion may partly antagonize FrA mediated effects in UC
cells. Combining FrA with a JNK1/2 inhibitor might
increase the efficacy of the marine compound. These
observations, however, require further investigations.
Caspase-dependent apoptosis pathways are known to
be often nonfunctional in human cancer cells. Overex-
pression of endogenous caspase inhibitors, mutations in
caspase genes and genes coding up- or downstream mol-
ecules, as well as low expression of these genes were
found to be causative [25]. In addition, more than 50%
of all human tumors (and >60% of UC neoplasms [6])
harbor mutant p53 with abrogated tumor suppressivefunction. This has often been associated with in-
creased tumor progression and negative treatment
outcome [7–9]. Thus, compounds which are able to
induce apoptosis independently of caspase- and p53-
activity are potentially of high clinical impact [9].
Interestingly, FrA mediated induction of apoptosis in
human UC cells did not require active caspases, al-
though the upregulation of active caspases was ob-
served in the treated cells. Therefore, we assume that
caspase activation is most probably a secondary event,
triggered by programmed death of cancer cells in a
caspase-independent manner [32, 33]. More import-
antly, using two different independent methods,
namely p53 gene silencing and inhibition of p53
Fig. 6 Effect of FrA in combination with cisplatin and gemcitabine. Cells were cotreated with different concentrations of the single substances or
their combination for 48 h at the constant molar ratios C(FrA) : C(Cis) = 1 : 4 (a) and C(FrA) : C(Gem) = 1 : 0.25 (b). The combinational index (CI)
values were calculated with CompuSyn software. The viability was examined using a trypan blue-based viability assay
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FrA-induced apoptosis could not be abolished by p53
alterations. In line with these results, FrA was active
in UC cells bearing both wild-type (RT112, RT4, and
HT-1197 cells) and mutant (T-24 and TCC-SUP cells)
p53 [19]. Interestingly, FrA appeared to be even
slightly more effective in RT112 cells with silenced or
inhibited p53. In contrast, in both experiments
cisplatin was significantly less active in cells with
either silenced or inhibited p53, demonstrating a p53-
dependence of cytotoxicity of this classical anti-cancer
agent. In the past decade, there are different hints
that p53 engages powerful pro-survival pathways
along with its tumor suppressive function [34]. This
effect strongly depends on the cell type, the specific
stimulus and its severity. In fact, unincisive stimuli
can induce slight and temporary p53-dependent cell
cycle arrest leading to DNA reparation. An explan-
ation for the increase of FrA cytotoxicity in p53-
deficient/suppressed RT112 cells may be a very low
interaction of FrA with the DNA damaging system,
leading to the activation of the pro-survival function
of p53 (which is also in line with the observed slight
activation of p21 expression–one of the best studied
targets of p53). In contrast, cisplatin directly targets
DNA by the induction of crosslinks (which is usually
associated with the strong activation of p21 expres-
sion) [35], and therefore can be considered a “strong
stimulus” activating the pro-apoptotic functions of p53.
However, this issue requires further investigations.
Caspase-independent cell death (CICD) can be exerted
through different mechanisms including death receptor-
induced necroptosis as well as mitochondrial, lysosomal,
or endoplasmic reticulum stress [33, 36, 37]. While the
first mechanism requires the death ligand presence, the
latter three are often trigged by small molecules which
result in a mechanical damage of the respective cellularstructures [36, 38]. Different proteins which are released
during these events lead to the caspase-independent
apoptosis not requiring active p53 protein. Thus, mito-
chondrial outer membrane permeabilization (MOMP)
can cause the release of HtrA2/Omi, endonuclease G
and AIF, while lysosomal membrane permeabilization
(LMP) leads to the release of cathapsins, and endoplas-
mic reticulum (ER) stress–to calcium release, conse-
quently leading to the activation of nonlysosomal
cysteine proteases calpains [33, 36]. One of these mecha-
nisms may explain caspase- and p53-independent char-
acter of FrA-induced apoptosis in UC cells. However,
further investigations are required to prove these
assumptions.
Recently, autophagy has been reported to be an im-
portant drug-resistance and pro-survival mechanism in
UC [10, 13, 28]. Indeed, inhibition of basal levels of
autophagy lead to UC cell death and re-sensitized cancer
cells to chemotherapy [10, 13]. Here, we could demon-
strate that FrA is capable to induce apoptosis and–un-
like other cytotoxic compounds–simultaneously inhibit
autophagy in UC cells.
Finally, FrA revealed a strong synergistic effect
when combined with cisplatin and gemcitabine in
RT112 cells. This effect may at least in part be ex-
plained by the ability of FrA to inhibit pro-survival
autophagy, as similar effects were observed previously
when combining cisplatin with autophagy inhibition
with in UC cells [10].
In vivo studies are an essential step for the further
preclinical and clinical development of anticancer
agents. Recently, it has been shown that daily intraven-
ous (i.v.) injections are the best way of FrA administra-
tion providing the highest values of maximum plasma
concentration of this drug [39]. Therefore, it is highly
recommended to use the i.v. administration for future
in vivo studies of FrA in models of human UC.
Dyshlovoy et al. BMC Cancer  (2017) 17:93 Page 9 of 10Conclusions
In conclusion, the marine triterpene glycoside frondo-
side A (FrA) is an interesting compound revealing high
efficacy in human UC cells. A unique combination of
properties including (i) induction of apoptosis not
requiring active caspases and p53, (ii) inhibition of
pro-survival autophagy and (iii) increased activity when
combined with classical cytotoxic agents makes the FrA
a very promising candidate for the treatment of UC.
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